-
Request for Information (RFI): Seeking Input on Existing Study Populations with Multi-Cancer Detection (MCD) Test Results and Available Samples for Germline Testing
- Notice NOT-CA-24-046 from the NIH Guide for Grants and Contracts
-
Notice of Intent to Publish a Funding Opportunity Announcement for Addressing Barriers to Healthcare Transitions for Survivors of Childhood and Adolescent Cancers (R01 Clinical Trial Optional)
- Notice NOT-CA-24-048 from the NIH Guide for Grants and Contracts
-
Notice of Special Interest (NOSI): Exploring the Effects of Endocannabinoids and Exogenous Cannabinoids on Brain Development
- Notice NOT-DA-25-030 from the NIH Guide for Grants and Contracts
-
Notice of Cancellation of the June 18, 2024 Application Receipt Date for RFA-EY-23-001 "BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed)"
- Notice NOT-EY-24-005 from the NIH Guide for Grants and Contracts
-
Standardized Ocular Imaging Expectations for Clinical and Nonclinical Research Funded by NEI
- Notice NOT-EY-24-006 from the NIH Guide for Grants and Contracts
-
Notice of Change to NHGRI-specific language in RFA-HG-23-018, Investigator-Initiated Research in Genomics and Health Equity (R21 Clinical Trial Optional)
- Notice NOT-HG-24-032 from the NIH Guide for Grants and Contracts
-
Notice to change the expiration date of PAR-21-254: Investigator Initiated Research in Computational Genomics and Data Science (R01 Clinical Trial Not Allowed)
- Notice NOT-HG-24-033 from the NIH Guide for Grants and Contracts
-
Notice to change the expiration date of PAR-21-255: Investigator Initiated Research in Computational genomics and Data Science (R21 Clinical Trial Not Allowed)
- Notice NOT-HG-24-034 from the NIH Guide for Grants and Contracts
-
Notice to Extend PAR-23-093, Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R01 Clinical Trial Optional)
- Notice NOT-MH-24-260 from the NIH Guide for Grants and Contracts
-
Notice to Extend PAR-23-101, Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R21 Clinical Trial Optional)
- Notice NOT-MH-24-261 from the NIH Guide for Grants and Contracts
-
Notice to Extend PAR-23-095, Innovative Mental Health Services Research Not Involving Clinical Trials (R01 Clinical Trials Not Allowed)
- Notice NOT-MH-24-265 from the NIH Guide for Grants and Contracts
-
Notice of Cancellation of the June 07, 2024, Application Receipt Date for RFA-MH-24-280 "BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01 Clinical Trial Not Allowed)"
- Notice NOT-MH-24-275 from the NIH Guide for Grants and Contracts
-
Request for Information (RFI): BRAIN Initiative: Opportunities and Challenges for Coordinated Neural Stimulating and Recording Efforts to Advance Understanding of Human Neuroscience and Behavior
- Notice NOT-NS-24-080 from the NIH Guide for Grants and Contracts
-
Notice of Special Interest (NOSI): Promoting Data Reuse for Health Research
- Notice NOT-OD-24-096 from the NIH Guide for Grants and Contracts
-
Notice of Fiscal Policies in Effect for FY 2024
- Notice NOT-OD-24-109 from the NIH Guide for Grants and Contracts
-
Notice of Legislative Mandates in Effect for FY 2024
- Notice NOT-OD-24-110 from the NIH Guide for Grants and Contracts
-
Retirement of the eRA Commons Quick Queries Page
- Notice NOT-OD-24-111 from the NIH Guide for Grants and Contracts
-
Notice to Extend the Expiration Date for the Mentored Patient-Oriented Research Career Development Awards (Parent K23s)
- Notice NOT-OD-24-113 from the NIH Guide for Grants and Contracts
-
Publication of the Revised NIH Grants Policy Statement (Rev. April 2024) for Fiscal Year 2024
- Notice NOT-OD-24-115 from the NIH Guide for Grants and Contracts
-
Notice of Information: Research Opportunities Centering the Health of Women Across the HIV Research Continuum
- Notice NOT-OD-24-117 from the NIH Guide for Grants and Contracts
-
Notice of Question and Answer "Office Hours" with NIH Staff for the Multi-Sectoral Preventive Interventions (MSPI) Research Network: PAR-24-053 (UG3/UH3, Clinical Trial Required) and RFA-OD-24-006 (U24, Clinical Trial Not Allowed)
- Notice NOT-OD-24-120 from the NIH Guide for Grants and Contracts
-
Notice of Information: Technical Assistance Webinars for PAR-24-206: Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN) (U54 Clinical Trial Optional)
- Notice NOT-TR-24-024 from the NIH Guide for Grants and Contracts
-
Notice of Special Interest (NOSI) on Catalyzing Research and Training on the Impact of HIV on the Health Across the Lifespan of Women Living with HIV Through Administrative Supplements to Existing Fogarty International Centers HIV Programs
- Notice NOT-TW-24-005 from the NIH Guide for Grants and Contracts
-
Type 1 Diabetes TrialNet Clinical Network Hub (U01 Clinical Trial Not Allowed)
- Funding Opportunity RFA-DK-25-005 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to continue support for the Type 1 Diabetes TrialNet Clinical Network Hub (HUB), a screening and clinical activities coordination unit for clinical trials focusing on the prevention of and early intervention in type 1 diabetes (T1D). The main objective of the HUB is to increase the efficiency and productivity of the TrialNet network by providing coordination of communications and outreach and developing new tools and approaches to increase screening, recruitment and retention. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.
-
Hazardous Materials Worker Health and Safety Training (U45 Clinical Trials Not Allowed)
- Funding Opportunity RFA-ES-24-001 from the NIH Guide for Grants and Contracts. NIEHS invites applications for cooperative agreements to support the development of model programs for the training and education of workers engaged in activities related to hazardous materials and waste generation, removal, containment, transportation and emergency response. This funding opportunity announcement aims to prevent work-related harm through safety and health training. The training programs will transmit skills and knowledge to workers in how best to protect themselves and their communities from exposure to hazardous materials encountered during hazardous waste operations, hazardous materials transportation, environmental restoration of contaminated facilities or chemical emergency response. A variety of sites, such as those involved with chemical waste cleanup and remedial action and transportation-related chemical emergency response, may pose severe health and safety concerns to workers and the surrounding communities. These sites contain many hazardous substances, sometimes unknown, and often a site is uncontrolled. A major goal of the Worker Training Program (WTP) is to support institutional competency-building for the development and delivery of model training and education programs.
-
Advancing HIV service delivery through pharmacies and pharmacists (R01 Clinical Trial Optional)
- Funding Opportunity RFA-MH-25-185 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to solicit research designed to capacitate, transform, and scale the delivery of HIV testing, prevention, and care services through pharmacists and pharmacies in US and/or global settings. This includes theadvancement of training curricula to enable pharmacy students, pharmacists, pharmacies, and pharmacy systems to deliver the spectrum of needed HIV services with ease, equity, and effectiveness. This NOFO uses the R01 grant mechanism, while RFA-MH-25-186 uses the R21 mechanism. Projects that lack preliminary data or that propose to pilot a novel intervention may be most appropriate for the R21 mechanism. Applications with preliminary data and those proposing large-scale clinical trials or longitudinal analyses should consider using the R01 mechanism.
-
Advancing HIV service delivery through pharmacies and pharmacists (R21 Clinical Trial Optional)
- Funding Opportunity RFA-MH-25-186 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to solicit research designed to capacitate, transform, and scale the delivery of HIV testing, prevention, and care services through pharmacists and pharmacies in US and/or global settings. This includes theadvancement of training curricula to enable pharmacy students, pharmacists, pharmacies, and pharmacy systems to deliver the spectrum of needed HIV services with ease, equity, and effectiveness. This NOFO uses the R21 grant mechanism, while RFA-MH-25-185 uses the R01 mechanism. Projects that lack preliminary data or that propose to pilot a novel intervention may be most appropriate for the R21 mechanism. Applications with preliminary data and those proposing large-scale clinical trials or longitudinal analyses should consider using the R01 mechanism.
-
Lasker Clinical Research Scholars Program (Si2/R00 Clinical Trial Optional)
- Funding Opportunity PAR-24-202 from the NIH Guide for Grants and Contracts. This FOA encourages applications for the Lasker Clinical Research Scholars Program for the purpose of supporting the research activities during the early stage careers of independent clinical researchers. The program offers the opportunity for a unique bridge between the NIH intramural and extramural research communities and contains two phases. In the first phase, Lasker Scholars will receive appointments for up to 5-7 years as tenure-track investigators within the NIH Intramural Research Program with independent research budgets. In the second phase, successful scholars will receive up to 3 years of NIH support for their research at an extramural research facility; or, the Scholar can be considered to remain as an investigator within the intramural program.
|
|
|